Supplementary Tables

Table S1. Clinical characteristics of patient studies in TCGA cohort

Clinical Eastons	C4 - 4	Number of cases		
Clinical Factors	Status	TCGA cohort (<i>n</i> =4,231)	Study cohort (n=2210)	
	Age≤45	425	226	
1 4 00	45 <age≤65< td=""><td>1816</td><td colspan="2">920</td></age≤65<>	1816	920	
Age	Age>65	1933	1035	
	Not reported	57	29	
	Age≤45	387	207	
A4 dia	45 <age≤65< td=""><td>1662</td><td colspan="2">827</td></age≤65<>	1662	827	
Age at diagnosis	Age>65	2125	1147	
	Not reported	57	29	
Gender	Male	1949	1084	
Gender	Female	2282	1126	
	I&II	1833	884	
Tumor Stage	III&IV	1120	659	
o .	Not reported	1278	667	
Vital Status	Alive	2828	823	
Vital Status	Dead	1403	1387	
	>3.5 years (dead, alive)	1133	1133	
Survival Time	≤3.5 years (dead)	1077	1077	
	≤3.5 years (alive)	1994	-	
	Unknown	27	-	

Table S2. Survival distribution of TCGA cohort under different cutoffs.

	No. of cases				
Cutoff (year)	Survival > Cutoff years	Survival ≤ Cutoff years			
1	3216	459			
1.5	2558	671			
2	2047	824			
2.5	1680	933			
3	1364	1021			
3.5	1133	1077			
4	962	1131			
4.5	800	1181			
5	695	1210			
5.5	577	1245			
6	488	1262			

Table S3. Expression summary of lncRNA signature

	TCGA cohort			Study cohort		
LncRNA	min	median	max	min	median	max
ENSG00000206567	0.031	0.888	14.450	0.047	0.873	13.821
PCAT29	0	0.035	11.851	0	0.032	2.573
ENSG00000257989	0	0.027	58.813	0	0	58.813
LOC388282	0	0.056	16.258	0	0.059	16.258
LINC00339	0.097	8.230	165.091	0.501	8.408	47.036

Table S4. Time-dependent ROC analysis of the 5-lncRNA signature on individual cancers (overall TCGA cohort)

Cancer Type	Survival AUC		Company Trump	Survival AUC		
	5-year	3-year		Cancer Type	5-year	3-year
BLCA	0.64	0.63		LIHC	0.76	0.73
BRCA	0.65	0.60		LUAD	0.62	0.61
CESC	0.60	0.69		LUSC	0.49	0.51
CHOL	0.79	0.81		OV	0.61	0.64
COAD	0.66	0.65		PAAD	-	0.64
DLBC	-	1.00		READ	0.90	0.79
ESCA	0.82	0.54		SARC	0.56	0.61
GBM	-	0.79		SKCM	0.62	0.57
HNSC	0.51	0.63		STAD	0.58	0.56
KICH	0.89	0.93		THYM	0.94	0.93
KIRC	0.72	0.69		UCEC	0.60	0.67
KIRP	0.55	0.77		UCS	0.78	0.66
LAML	0.75	0.76		UVM	-	1.00
LGG	0.80	0.67				

Performance for some cancer types, including ACC, PCPG, PRAD, THCA, MESO and TGCT, cannot be reported due to the insufficient cases or censored data for survival analysis.